PUMA BIOTECHNOLOGY INCPBYI
ASignal's systematic analysis rates PBYI as Bullish.
Reflects the latest available analysis · analyzed Oct 2, 2026
The case on PBYI
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin (74.83%) indicating pricing power
- Low debt-to-equity ratio (0.03x) signaling strong financial health
- Positive free cash flow ($32.47M) and operating cash flow ($41.15M)
- Return on equity above 20% (21.97%) reflecting high capital efficiency
- Current price above both SMA20 and SMA50, indicating uptrend
- MACD slightly above signal line with positive histogram, suggesting bullish momentum
- RSI at 65.15, approaching overbought territory
- Limited retail sentiment data (zero Reddit mentions)
- No recent news coverage to confirm positive momentum
- Forward P/E (28.01x) significantly higher than current P/E (19.23x), suggesting earnings growth expectations are priced in
See the full verdict on PBYI
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes PBYI
Most investors never get a second opinion, let alone several. ASignal runs PBYI past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.